Table of contents
At a glance
How do you manage hybrid paper and electronic records under Part 11?
Paper and electronic components can form one FDA-regulated record if applicable predicate rules are met and content and meaning are preserved. Define which information is authoritative in each medium, how the components link and which version was reviewed. Printing the record does not automatically remove Part 11 from scope. A static report cannot always replace the dynamic context needed to understand the data.
- Describe the complete validation package for both media.
- Link the test stand and subsequent modifications unambiguously.
- Plan the storage and retrieval of all required components together.
1. Describe a demonstration of evidence for both media
Do not begin by asking whether paper or electronic systems are inherently superior. Instead, determine the specific information required for the particular process. For a laboratory test, for example, sample data, measurement files, calculations, report, and review notes may all be necessary. The mere presence of a single cover sheet does not automatically constitute a complete record.
The FDA Scope Guidance explicitly permits the coexistence of paper, electronic record, and signature components under the aforementioned conditions. The laboratory examples presented herein assume the appropriate Drug CGMP Scope. The required contents are determined by the applicable regulatory requirement and the actual activities performed.
2. Establish the actual use
Please ask which information the reviewer actually uses. Does the reviewer consider only a sufficient paper record, or also electronic curves, integration parameters, comments, and change events? The FDA takes this business practice into account when classifying under Part 11. An internal policy stating "paper takes precedence" is insufficient if the workflow operates differently.
Maintain integrity where data are first created. A device may generate a static original record; other laboratory instruments produce dynamic records containing required processing and contextual information. The decision therefore must not solely depend on whether a printer is available or whether a PDF can be exported.
3. Complete a form for the hybrid documentation template
Example: The L-28 inspection is electronically evaluated and confirmed on a paper report. The following table describes the intended test suite. The identifiers, revisions, and file locations apply only to this example and do not represent tested product functions.
| Component | Substantive content in the example | Compound | Review/Access task |
|---|---|---|---|
| Sample record P-28 | Identity, Receipt, Sample Traceability | Testing L-28 and Batch C-6 | Verify the correct sample and assignment. |
| Data set M-28 | Collected electronic data together with required context | L-28; fixed evaluation status A2 | Assess electronically required data and history. |
| Calculation K-28, Revision 2 | Used values, units, and factors | M-28/A2; Report B-28/2 | Trace the calculation pathway and source data. |
| Paper report B-28, Revision 2 | Results presentation and intended manual confirmation | L-28; M-28/A2; K-28/2 | Understand the scope and significance of validation. |
| Review note R-28 | Which components and which batch were reviewed? | Unique references to the four aforementioned sections | Later it will be possible to determine what was actually assessed. |
4. Link content, status, and signature
An identical file name does not constitute a reliable indication of identical content. Establish a combination of process identifier, revision or evaluation status, and controlled storage designation. The specific technical implementation is freely selectable; it must preserve the required relationship in a traceable manner.
When a handwritten signature is executed on an electronic record, the linkage as specified in §11.70 remains relevant. From this, a universal requirement for electronic signatures is not inferred. In a hybrid procedure, it must be clearly established which statement applies to which document and how a misleading transfer to another record is prevented.
5. Explicitly address the change based on the expression of the release
A common edge case arises when the report has already been printed, while the electronic evaluation is still being updated. Define how the previously printed version remains clearly identifiable and how the subsequent assessment is documented. Simply replacing the printout without explaining the relationship may lead to confusion in the inspection process.
In the example, a value is changed from 4.20 to 4.35. The difference is 0.15. This is not a predefined tolerance and does not automatically determine validity or release. First, the reason for the change, the data basis, and the impact of the change must be evaluated.
| Situation | Own Required Rules | Verifiable observation |
|---|---|---|
| B-28/2 was prepared from A2 and submitted for review. | Clear reference to A2 and K-28/2 obtained. | The paper record can be traced back to the corresponding electronic record. |
| Electronic record version A3 contains 4.35 instead of 4.20 | Changes and justifications are evaluated for clarity; prior data remain intact within the required context. | A2 and A3 are not combined without clear identification. |
| A new report B-28/3 is required | Labeling and intended testing align with the updated status. | Confirmation of B-28/2 does not appear implicitly as a review of B-28/3. |
| Retrieval of a completed process after completion | Both media and the relevant change notification are retrievable. | The reviewer can determine the actually assessed stage. |
6. Verify the complete required set
§211.194(a)(8) requires, within the relevant laboratory area, a note from a second person reviewing the original records for accuracy, completeness, and conformity to established standards. A review limited to the final result value may be insufficient for this purpose. The specific elements that constitute such a review must arise from the particular inspection procedure.
Organise access so that paper and necessary electronic content can be genuinely evaluated together. The reviewer must be granted appropriate read rights and a clear procedural approach. A note "reviewed" without visible coverage does not clearly indicate whether only the report or both the report and the underlying required data were assessed.
7. Plan storage as an integrated task
For the hybrid set, the required contents must remain available during the applicable deadline. A retrievable paper archive provides limited value if the necessary electronic evaluation cannot be understood due to the absence of appropriate reading capabilities. Conversely, a digital file does not automatically replace a still required paper component.
§211.180 addresses, among other things, availability of records and original and accurate copies. The FDA guidance elaborates on the retention of content and its significance. A media migration or destruction of originals constitutes a separate decision requiring appropriate justifications; the hybrid configuration alone does not constitute authorization for such actions.
8. Make knowledge transfers manageable even in small teams
Assign a responsible person and the expected outcome for each media change. Who generates the report, who checks the status, who leads the correction, and who ensures subsequent access? This assignment constitutes an independent organizational workflow support and is not a universally mandated role hierarchy.
Test the procedure once using a deliberately altered batch and once using a missing ingredient. Such scenario checks demonstrate whether the linkage logic is understandable. They do not replace a full evaluation of the specific system, but do provide targeted evidence for identified transfer risks.
- The essential components and relevant media for each ingredient are to be determined.
- Define a common transaction ID and a controlled reference to the applicable version.
- Attach paper certification with the actually assessed content.
- Address changes resulting from print and review explicitly.
- Provide access to all required review components.
- Check storage, legibility and recovery together.
- Document open media breaches and responsibilities.
Project experience and collaboration
Link paper approval to the corresponding electronic data version
Your process owners select a signed paper report. We trace its conclusion back to the electronic data. If the reviewed version can be identified, we test the existing links and subsequent retrieval. Where the version, attachments or important dynamic information are missing, we plan additional evidence or a revised recording process. Your team can then maintain the relationship between the records through changes and archiving.
Frequently asked questions about Hybrid records
Are hybrid records generally permitted in the FDA context?
The scope-guidance explicitly addresses such combinations. The prerequisite is that the relevant predicate rules remain satisfied and that the content and meaning of the records are preserved. A general authorization for arbitrary, unlinked paper and file collections does not follow.
Sources: [1]
Is the signed paper report always the sole original evidence?
Must paper and electronic records contain exactly the same information, duplicated?
Does the same test number apply to the report and the file?
What happens if data is modified after print?
Assess and document the change and its impact on reporting and testing. The previous expression must not be misleadingly presented as evidence for the current electronic version. Whether a retest or confirmation is required follows from the specific process and the nature of the change.
Must a laboratory inspector also have access to the electronic source data?
The review under §211.194(a)(8) addresses the required original records. If the paper report does not fully represent them, the necessary electronic content must be included in the review. The FDA specifically clarifies this point with respect to dynamic laboratory records and static prints.
Does a hybrid process require automatic electronic signatures?
Can a scan always replace the signed paper document thereafter?
Generally, an accurate copy may be retained in lieu of the original; § 211.180(d) permits originals or true copies. A scan must contain the required content and maintain the integrity and meaning of the original, including the signature, and must be appropriately reviewed. If electronic records are maintained instead of paper, their classification under EU GMP Annex 11 must be determined based on the specific record and intended use. Whether paper records may be destroyed thereafter remains a separate decision based on applicable guidelines.
Do all components need the same retention period?
Not every component requires an independent retention period. However, information that enables an ongoing record to remain understandable must remain available. For batch-specific records, § 211.180(a) mandates a minimum retention period of one year after batch expiration; for certain OTC products without an expiration date, due to the exception in § 211.137, the retention period is three years after the batch is distributed. A deletion rule for individual components must not disrupt the required overall context.
What documentation should we retain for the adoption of the current process?
Sources and review date
Source date: 7 October 2026. eCFR notice period until 5 October 2026; separate consideration of binding regulatory text and non-binding FDA Guidance. Examples and tables are internal work aids and do not represent completed product testing.
- FDA: Part 11 – Scope and ApplicationFinal guidance. The PDF is dated August 2003 and the status page September 2003. See sections I and III.A–C.
- 21 CFR §211.194 – Laboratory recordseCFR notice until 05.10.2026; paragraphs (a)(1)–(8), (b)–(e).
- FDA: Data Integrity and Compliance With Drug CGMP – Questions and AnswersFDA Data Integrity Q&A, December 2018: Questions 1(d), 9, and 10 regarding dynamic records, valid copies, and electronic laboratory originals.
- 21 CFR Part 11 – Electronic Records; Electronic SignatureseCFR display until 05.10.2026; §§11.1–11.300.
- 21 CFR §211.180 – General requirements21 CFR § 211.180: Paragraph (a) regarding minimum retention periods for batch-specific records including certain OTC exemptions, (c) regarding inspection access, and (d) regarding originals or true copies.
Sources checked: .
Jointly develop the specific evidence process
We assist you in clearly linking the components of your hybrid workflow and establishing appropriate review and change documentation. Process owners determine the specific information required by the individual process.
- Computer system validation →
Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

